Lixte Biotechnology Holdings Stock Total Asset
| LIXT Stock | USD 1.99 0.08 4.19% |
Lixte Biotechnology Holdings fundamentals help investors to digest information that contributes to Lixte Biotechnology's financial success or failures. It also enables traders to predict the movement of Lixte Stock. The fundamental analysis module provides a way to measure Lixte Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lixte Biotechnology stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 4.3 M | 2.2 M |
Lixte | Total Asset |
Lixte Biotechnology Holdings Company Total Asset Analysis
Lixte Biotechnology's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Lixte Biotechnology Total Asset | 4.31 M |
Most of Lixte Biotechnology's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lixte Biotechnology Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lixte Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Lixte Biotechnology is extremely important. It helps to project a fair market value of Lixte Stock properly, considering its historical fundamentals such as Total Asset. Since Lixte Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lixte Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lixte Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Lixte Total Asset Historical Pattern
Today, most investors in Lixte Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lixte Biotechnology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lixte Biotechnology total asset as a starting point in their analysis.
Lixte Biotechnology Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Lixte Total Assets
Total Assets |
|
Based on the latest financial disclosure, Lixte Biotechnology Holdings has a Total Asset of 4.31 M. This is 99.94% lower than that of the Biotechnology sector and 99.78% lower than that of the Health Care industry. The total asset for all United States stocks is 99.99% higher than that of the company.
Lixte Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lixte Biotechnology's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics of similar companies.Lixte Biotechnology is currently under evaluation in total asset category among its peers.
Lixte Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in Lixte Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lixte Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lixte Biotechnology's value.| Shares | Hightower Advisors, Llc | 2024-09-30 | 99.4 K | Fny Investment Advisers, Llc | 2024-06-30 | 50.3 K | Ethos Financial Group Llc | 2024-09-30 | 24.8 K | Geode Capital Management, Llc | 2024-09-30 | 17.2 K | Tower Research Capital Llc | 2024-09-30 | 2.1 K | Ubs Group Ag | 2024-09-30 | 367 | Bank Of America Corp | 2024-09-30 | 16.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 |
Lixte Fundamentals
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.87 | ||||
| Current Valuation | 6.59 M | ||||
| Shares Outstanding | 2.25 M | ||||
| Shares Owned By Insiders | 20.40 % | ||||
| Shares Owned By Institutions | 9.64 % | ||||
| Number Of Shares Shorted | 136.43 K | ||||
| Price To Earning | (2.96) X | ||||
| Price To Book | 12.00 X | ||||
| EBITDA | 3.21 K | ||||
| Net Income | (5.09 M) | ||||
| Cash And Equivalents | 7.74 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 313.86 K | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 15.10 X | ||||
| Book Value Per Share | 0.22 X | ||||
| Cash Flow From Operations | (4.29 M) | ||||
| Short Ratio | 0.31 X | ||||
| Earnings Per Share | (1.73) X | ||||
| Beta | -0.17 | ||||
| Market Capitalization | 4.72 M | ||||
| Total Asset | 4.31 M | ||||
| Retained Earnings | (48.48 M) | ||||
| Working Capital | 3.99 M | ||||
| Current Asset | 1.38 M | ||||
| Current Liabilities | 140 K | ||||
| Net Asset | 4.31 M |
About Lixte Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lixte Biotechnology Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.